{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:18:44Z","timestamp":1791778724188,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1053\/snuc.2002.31027","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T23:46:10Z","timestamp":1030232770000},"page":"133-140","source":"Crossref","is-referenced-by-count":274,"title":["Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings"],"prefix":"10.1053","volume":"32","author":[{"given":"Marion","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelf","family":"Valkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Jamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry K.","family":"Kvols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik J.","family":"Kwekkeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout A.P.","family":"Breeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuck","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/snuc.2002.31027_bib1","first-page":"437","article-title":"Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy","volume":"58","author":"De Jong","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/snuc.2002.31027_bib2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTA, Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D- Phe1]octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/snuc.2002.31027_bib4","first-page":"356","article-title":"Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues","volume":"43","author":"De Jong","year":"1999","journal-title":"Q J Nucl Med"},{"issue":"suppl 2","key":"10.1053\/snuc.2002.31027_bib5","first-page":"S219","article-title":"Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide","volume":"31","author":"Krenning","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1053\/snuc.2002.31027_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<767::AID-IJC17>3.0.CO;2-T","article-title":"Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver","volume":"81","author":"Slooter","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1053\/snuc.2002.31027_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin-analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/snuc.2002.31027_bib8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: First clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/cbr.1999.14.477","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide: Preliminary report in cancer patients","volume":"14","author":"Paganelli","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/snuc.2002.31027_bib10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s002590050268","article-title":"The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours","volume":"25","author":"Stolz","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib11","first-page":"111P","article-title":"Targeted radiotherapy with 90Y-SMT487 (OctreoTher): A phase I study","volume":"41","author":"Valkema","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib12","first-page":"223P","article-title":"High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model","volume":"40","author":"Erion","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L","article-title":"[177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy","volume":"92","author":"de Jong","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1053\/snuc.2002.31027_bib14","first-page":"1027P","article-title":"Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors: Preliminary results","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0024-3205(95)02082-T","article-title":"The somatostatin receptor family","volume":"57","author":"Patel","year":"1995","journal-title":"Life Sci"},{"key":"10.1053\/snuc.2002.31027_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"issue":"suppl 2","key":"10.1053\/snuc.2002.31027_bib17","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/annonc\/10.suppl_2.S17","article-title":"Somatostatin receptors: Present knowledge and future directions","volume":"10","author":"Schonbrunn","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/snuc.2002.31027_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00006231-199803000-00013","article-title":"Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy","volume":"19","author":"De Jong","year":"1998","journal-title":"Nucl Med Commun"},{"key":"10.1053\/snuc.2002.31027_bib19","first-page":"2002","article-title":"Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide","volume":"37","author":"Andersson","year":"1996","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"10.1053\/snuc.2002.31027_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000201382","article-title":"Internalisation of isotope-coupled somatostatin analogues","volume":"57","author":"Hofland","year":"1996","journal-title":"Digestion"},{"key":"10.1053\/snuc.2002.31027_bib21","first-page":"659","article-title":"Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes","volume":"57","author":"Duncan","year":"1997","journal-title":"Cancer Res"},{"key":"10.1053\/snuc.2002.31027_bib22","first-page":"1256","article-title":"Progressive nuclear translocation of somatostatin analogs","volume":"41","author":"Hornick","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/00006231-200011000-00015","article-title":"Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy","volume":"21","author":"Bernard","year":"2000","journal-title":"Nucl Med Commun"},{"key":"10.1053\/snuc.2002.31027_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib25","first-page":"1841","article-title":"Tumor response after [90Y-DOTA0, Tyr3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size","volume":"42","author":"De Jong","year":"2001","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"10.1053\/snuc.2002.31027_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000201387","article-title":"Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer","volume":"57","author":"Stolz","year":"1996","journal-title":"Digestion"},{"key":"10.1053\/snuc.2002.31027_bib27","first-page":"1025P","article-title":"Safety and efficacy of [Y-90-DOTA, Tyr(3)]octreotide (Y-90-SMT487; OCTREOTHER\u2122) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study","volume":"28","author":"Valkema","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib29","first-page":"792","article-title":"DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy","volume":"24","author":"Otte","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/snuc.2002.31027_bib31","first-page":"1026P","article-title":"Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: Tumour size versus curability","volume":"28","author":"De Jong","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib32","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31027_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1097-0215(20000820)90:4<186::AID-IJC2>3.0.CO;2-P","article-title":"Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy","volume":"90","author":"van Hagen","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1053\/snuc.2002.31027_bib34","first-page":"1158P","article-title":"RGD-DTPA-OCTREOTATE, an analogue for tumour imaging and radionuclide therapy","volume":"28","author":"De Jong","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"suppl 1","key":"10.1053\/snuc.2002.31027_bib35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000051861","article-title":"Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review","volume":"62","author":"Arnold","year":"2000","journal-title":"Digestion"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299802800319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299802800319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T20:21:12Z","timestamp":1555014072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299802800319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0001299802800319"],"URL":"https:\/\/doi.org\/10.1053\/snuc.2002.31027","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}